Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LX109 in nAMD
NCT06022744Phase 1Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
01
Overview
Phase 1, open-label trial of LX109 in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Adverse Event at 4 weeks. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
LX109
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06022744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022744.